Search

Anna J Hussey,1 Kevin Wing,2 Madonna Ferrone,1,3 Christopher J Licskai1,4– 6 1Asthma Research Group Windsor-Essex County Inc., Windsor, ON, Canada; 2London School of Hygiene and Tropical Medicine, London, UK; 3Hotel-Dieu Grace Healthcare, Windsor, ON, Canada; 4London Health Sciences Centre, London, ON, Canada; 5Lawson Health Research Institute, London, ON, Canada; 6Schulich School of Medicine and Dentistry, Western University, London, ON, CanadaCorrespondence: Christopher J LicskaiSchulich School of Medicine and Dentistry, Western University, London, ON, CanadaEmail chris.licskai@sjhc.London.on.caPurpose: Integrated disease management (IDM) for COPD in primary care has been primarily investigated under clinical trial conditions. We previously published a randomized controlled trial (RCT) where the IDM intervention improved quality of life (QoL) and exacerbation-related outcomes. In this study, we assess the same IDM intervention in a real-world evaluation and identify patient characteristics associated with improved outcomes.Methods: This historical cohort study included patients enrolled for 12 (± 3 months) in the Best Care COPD IDM program. The main outcome was a ≥ 3 point improvement in COPD assessment test (CAT). Secondary outcomes were COPD exacerbations requiring antibiotics and/or prednisone, unscheduled physician visits, emergency department visits and hospitalizations.Results: Data for 571 patients (all patients) were included, 158 met the reference RCT eligibility (RCT matched). Improved QoL was observed in 43% (95% CI:38.9,47.2) of all patients, 47% (95% CI:39.5,55.6) of RCT matched vs 92% (95% CI:79.2,95.1) in the reference RCT intervention arm (n=72). Reductions (12 months IDM vs prior year) were observed in the proportion of patients experiencing exacerbation-related events (all patients): antibiotics/prednisone (− 9.0%,95% CI:-13.9,-3.9); unscheduled physician (− 33.1%,95% CI:-38.2,-27.9); emergency department (− 9.6%,95% CI:-13.5,-5); and hospitalizations (− 6.8%,95% CI:-10.0,-3.7). For the RCT matched group all reductions were comparable to the reference RCT intervention arm. The strongest predictors of improved QoL were baseline CAT, CAT≥ 20 vs CAT< 10 (OR 15.6,95% CI:7.91,30.83), GOLD group B (OR 6.4,95% CI:3.42,11.85) and D (OR 5.64,95% CI:2.80,11.37) vs GOLD group A. Patients with prior antibiotic/prednisone use, FEV1 < 30% predicted and GOLD group D were less likely to have no urgent health service utilization (OR 0.5,95% CI:0.30,0.68), (OR 0.2,95% CI:0.07,0.78) and (OR 0.3,95% CI:0.14,0.51), respectively.Conclusion: Best Care COPD improved QoL and reduced exacerbation-related outcomes in a manner directionally similar to the RCT from which it emanated. Baseline QoL, exacerbation history, and GOLD category were identified as possible predictors of IDM impact and will inform future program development and resource allocation.Keywords: chronic disease management, COPD assessment test, health service utilization, health status, quality of life

Estimates of the spectrum and frequency of pathogenic variants in Parkinsons disease (PD) in different populations are currently limited and biased. Furthermore, although therapeutic modification of several genetic targets has reached the clinical trial stage, a major obstacle in conducting these trials is that PD patients are largely unaware of their genetic status and, therefore, cannot be recruited. Expanding the number of investigated PD-related genes and including genes related to disorders with overlapping clinical features in large, well-phenotyped PD patient groups is a prerequisite for capturing the full variant spectrum underlying PD and for stratifying and prioritizing patients for gene-targeted clinical trials. The Rostock Parkinsons disease (ROPAD) study is an observational clinical study aiming to determine the frequency and spectrum of genetic variants contributing to PD in a large international cohort. We investigated variants in 50 genes with either an established relevance for PD or possible phenotypic overlap in a group of 12 580 PD patients from 16 countries [62.3% male; 92.0% White; 27.0% positive family history (FH+), median age at onset (AAO) 59 years] using a next-generation sequencing panel. Altogether, in 1864 (14.8%) ROPAD participants (58.1% male; 91.0% White, 35.5% FH+, median AAO 55 years), a PD-relevant genetic test (PDGT) was positive based on GBA1 risk variants (10.4%) or pathogenic/likely pathogenic variants in LRRK2 (2.9%), PRKN (0.9%), SNCA (0.2%) or PINK1 (0.1%) or a combination of two genetic findings in two genes (∼0.2%). Of note, the adjusted positive PDGT fraction, i.e. the fraction of positive PDGTs per country weighted by the fraction of the population of the world that they represent, was 14.5%. Positive PDGTs were identified in 19.9% of patients with an AAO ≤ 50 years, in 19.5% of patients with FH+ and in 26.9% with an AAO ≤ 50 years and FH+. In comparison to the idiopathic PD group (6846 patients with benign variants), the positive PDGT group had a significantly lower AAO (4 years, P = 9 × 10-34). The probability of a positive PDGT decreased by 3% with every additional AAO year (P = 1 × 10-35). Female patients were 22% more likely to have a positive PDGT (P = 3 × 10-4), and for individuals with FH+ this likelihood was 55% higher (P = 1 × 10-14). About 0.8% of the ROPAD participants had positive genetic testing findings in parkinsonism-, dystonia/dyskinesia- or dementia-related genes. In the emerging era of gene-targeted PD clinical trials, our finding that ∼15% of patients harbour potentially actionable genetic variants offers an important prospect to affected individuals and their families and underlines the need for genetic testing in PD patients. Thus, the insights from the ROPAD study allow for data-driven, differential genetic counselling across the spectrum of different AAOs and family histories and promote a possible policy change in the application of genetic testing as a routine part of patient evaluation and care in PD.

This purpose of this qualitative study was to explore shared characteristics and local challenges of trauma-informed youth sport program design and implementation through the voices of ten program facilitators (e.g., director, trainer; 8 women, 2 men; average age of 36.2 years, SD = 6.03) across four U.S. regions. Within a postpositivist approach and through thematic analysis of semi-structured interviews (average length of 53 minutes), shared characteristics identified by facilitators included promoting a safe and supportive environment, cultivating healthy relationships among adults and peers, and intentional psychological and social skill-building (e.g., attentional cues). Facilitators also explained the importance of understanding the local context to engage youth and develop key strategies to mitigate challenges such as prioritizing the voices of youth involved in their programs, attending to staff needs and providing continual development and training, and collaboration among community partners to support their programmatic efforts. The study findings may be used to inform future research conceptualizing best practices for inclusive youth sport settings and provide added context for facilitators in the development, implementation, and sustainability of the trauma-informed approach.

BACKGROUND: Equine herpes virus type 1 (EHV-1) infection in horses is associated with respiratory and neurologic disease, abortion, and neonatal death. HYPOTHESIS: Vaccines decrease the occurrence of clinical disease in EHV-1-infected horses. METHODS: A systematic review was performed searching multiple databases to identify relevant studies. Selection criteria were original peer-reviewed research reports that investigated the in vivo use of vaccines for the prevention of disease caused by EHV-1 in domesticated horses. Main outcomes of interest included pyrexia, abortion, neurologic disease, viremia, and nasal shedding. We evaluated risk of bias, conducted exploratory meta-analyses of incidence data for the main outcomes, and performed a GRADE evaluation of the quality of evidence for each vaccine subtype. RESULTS: A total of 1018 unique studies were identified, of which 35 met the inclusion criteria. Experimental studies accounted for 31/35 studies, with the remainder being observational studies. Eight vaccine subclasses were identified including commercial (modified-live, inactivated, mixed) and experimental (modified-live, inactivated, deletion mutant, DNA, recombinant). Risk of bias was generally moderate, often because of underreporting of research methods, and sample sizes were small leading to imprecision in the estimate of the effect size. Several studies reported either no benefit or minimal vaccine efficacy for the primary outcomes of interest. Meta-analyses revealed significant heterogeneity was present, and our confidence in the quality of evidence for most outcomes was low to moderate. CONCLUSIONS AND CLINICAL IMPORTANCE: Our review indicates that commercial and experimental vaccines minimally reduce the incidence of clinical disease associated with EHV-1 infection.

BACKGROUND: Equine herpes virus type 1 (EHV-1) infection in horses is associated with upper respiratory disease, neurological disease, abortions, and neonatal death. REVIEW QUESTION: Does pharmacological therapy decrease either the incidence or severity of disease or infection caused by EHV-1 in domesticated horses? METHODS: A systematic review was preformed searching AGRICOLA, CAB Abstracts, Cochrane, PubMed, Web of Science, and WHO Global Health Index Medicus Regional Databases to identify articles published before February 15, 2021. Selection criteria were original research reports published in peer reviewed journals, and studies investigating in vivo use of therapeutic agents for prevention or treatment of EHV-1 in horses. Outcomes assessed included measures related to clinical outcomes that reflect symptomatic EHV-1 infection or virus infection. We evaluated risk of bias and performed a GRADE evaluation of the quality of evidence for interventions. RESULTS: A total of 7009 unique studies were identified, of which 9 met the inclusion criteria. Two studies evaluated valacyclovir or small interfering RNAs, and single studies evaluated the use of a Parapoxvirus ovis-based immunomodulator, human alpha interferon, an herbal supplement, a cytosine analog, and heparin. The level of evidence ranged between randomized controlled studies and observational trials. The risk of bias was moderate to high and sample sizes were small. Most studies reported either no benefit or minimal efficacy of the intervention tested. CONCLUSIONS AND CLINICAL IMPORTANCE: Our review indicates minimal or limited benefit either as a prophylactic or post-exposure treatment for any of the studied interventions in the mitigation of EHV-1-associated disease outcome.

Equine herpesvirus-1 (EHV-1) is a highly prevalent and frequently pathogenic infection of equids. The most serious clinical consequences of infection are abortion and equine herpesvirus myeloencephalopathy (EHM). The previous consensus statement was published in 2009 and considered pathogenesis, strain variation, epidemiology, diagnostic testing, vaccination, outbreak prevention and control, and treatment. A recent survey of American College of Veterinary Internal Medicine large animal diplomates identified the need for a revision to this original consensus statement. This updated consensus statement is underpinned by 4 systematic reviews that addressed key questions concerning vaccination, pharmaceutical treatment, pathogenesis, and diagnostic testing. Evidence for successful vaccination against, or effective treatment of EHV-1 infection was limited, and improvements in experimental design and reporting of results are needed in future studies of this important disease. This consensus statement also updates the topics considered previously in 2009.

The 2023 budgeting cycle in California was much different from the previous year. California’s finances, always topsy-turvy, faced a dramatic reversal of fortune as surplus turned to deficit.  Nonetheless, the state was able to weather the storm and avoid deep spending cuts, thanks to a combination of good economic times in years past and politically expedient decisions by the Governor and Legislature.  However, delayed tax collections and projections for structural deficits, even absent a recession, meant storm clouds were on the horizon as the year drew to a close.  The tough decisions that were sidestepped in 2023 might have to be made in 2024.

BACKGROUND: Equine herpes virus type 1 (EHV-1) infection in horses is associated with upper respiratory disease, neurological disease, abortions, and neonatal death. OBJECTIVE: To determine if there is an association between the level and duration of EHV-1 viremia and either abortion or equine herpesvirus myeloencephalopathy (EHM) in domesticated horses? METHODS: A systematic review was performed searching numerous databases to identify peer reviewed reports that evaluated viremia and EHM, or viremia and abortion published before January 19, 2021. Randomized controlled trials and observational studies were assessed for risk of bias or publication quality. RESULTS: A total of 189 unique studies were identified, of which 34 met the inclusion criteria. Thirty studies evaluated viremia and neurologic outcomes including 4 observational studies. Eight experimental studies examined viremia and abortion, which used the Ab4 and OH03 virus strains or recombinant Ab4 derivatives. Incidence rates for both EHM and abortion in experimental studies varied among the studies as did the level of evidence. Viremia was generally detectable before the onset of either EHM or abortion. Risk of bias was generally low to moderate, sample sizes were small, and multiple studies reported negative outcome data. CONCLUSIONS AND CLINICAL IMPORTANCE: The results of this study support that viremia is regularly present before EHM or abortion occurs. However, no inferences could be made about the relationship between the occurrence of either neurological signs or abortion and the magnitude or duration of viremia.

BACKGROUND: Equine herpesvirus type 1 (EHV-1) infection is associated with upper respiratory disease, EHM, abortions, and neonatal death. RESEARCH QUESTIONS: Are nasal secretions a more sensitive biological sample compared to blood for the detection of EHV-1 infection? How long is EHV-1 detectable after primary infection by PCR? METHODS: MedLine and Web of Science searches identified original peer-reviewed reports evaluating nasal shedding and viremia using virus isolation methods or PCR published in English before October 9, 2023. RESULTS: Sixty experimental and 20 observational studies met inclusion criteria. EHV-1 detection frequency by qPCR in nasal secretions and blood from naturally-infected horses with fever and respiratory signs were 15% and 9%, respectively; qPCR detection rates in nasal secretions and blood from horses with suspected EHM were 94% and 70%, respectively. In experimental studies the sensitivity of qPCR matched or exceeded that seen for virus isolation from either nasal secretions or blood. Detection of nasal shedding typically occurred within 2 days after EHV-1 inoculation with a detection period of 3 to 7 days. Viremia lasted 2 to 7 days and was usually detected ≥1 days after positive identification of EHV-1 in nasal secretions. Nasal shedding and viremia decreased over time and remained detectable in some horses for several weeks after inoculation. CONCLUSIONS AND CLINICAL IMPORTANCE: Under experimental conditions, blood and nasal secretions have similar sensitivity for the detection of EHV-1 when horses are sampled on multiple consecutive days. In contrast, in observational studies detection of EHV-1 in nasal secretions was consistently more successful.

Abstract Despite obvious similarities in their electronic and crystallographic structures, it remains unclear whether the interactions that shape the normal and superconducting (SC) state properties of high-T c cuprates and infinite-layer nickelates (ILNs) have the same origin. This question has been brought into sharper focus with recent studies on ILNs of improved crystallinity that reveal a SC dome of comparable extent and similar transport properties above T c as the hole-doped cuprates. The evolution of these properties in the magnetic-field-induced normal state, however, has yet to be determined. Here, we examine the magnetotransport properties of new-generation Nd1−x Sr x NiO2 films in the T → 0 limit across the phase diagram in fields up to 54 T. This extensive study reveals that the limiting low-T form of the normal-state resistivity in ILNs exhibits non-Fermi-liquid behaviour over an extended doping range inside the SC dome, rather than at a singular quantum critical point. While there are clear differences in the charge dynamics of ILNs and cuprates, most notably in the magnetoresistance, our findings reveal that both systems exhibit anomalous metallicity characteristic of a quantum critical phase.

Abstract We present a versatile optical setup for high-resolution neutron imaging with an adaptable field of view and magnification that can resolve individual neutron absorption events with an image intensifier and a CMOS camera. Its imaging performance is characterized by evaluating the resolution limits of the individual optical components and resulting design aspects are discussed. Neutron radiography measurements of a Siemens star pattern were performed in event mode acquisition comparing two common high-resolution neutron scintillators, crystalline Gadolinium Gallium Garnet (GGG) and powdered Gadolinium Oxysulfide (GOS). An analysis of the light signature caused by neutron absorption events is performed and some resulting issues for both GGG and GOS regarding optical system design are addressed. Both scintillators reach similar resolution (4–5 $${\upmu }$$ μ m) in event mode acquisition despite different light emission characteristics. The findings suggest that, in the case of GOS, the resolution is limited by the size of the light clusters which in turn originate from the photon scattering at the boundaries of the powder particles comprising it, while with GGG the lower light conversion efficiency makes it challenging to collect enough photons to trigger sufficient signal amplification in the image intensifier. Overall, the proposed event-based evaluation of scintillators allows for quantifying and optimizing various design parameters, which is much more complex than adopting conventional methods based on integrated images.

Abstract Modulating inflammation is critical to enhance nerve regeneration after injury. However, clinically applicable regenerative therapies that modulate inflammation have not yet been established. Here, we demonstrate synergistic effects of the combination of an HMG-CoA reductase inhibitor, statin/fluvastatin and critical components of the extracellular matrix, Matrix-Bound Nanovesicles (MBV) to enhance axon regeneration and neuroprotection after mouse optic nerve injury. Mechanistically, co-intravitreal injections of fluvastatin and MBV robustly promote infiltration of monocytes and neutrophils, which lead to RGC protection and axon regeneration. Furthermore, monocyte infiltration is triggered by elevated expression of CCL2, a chemokine, in the superficial layer of the retina after treatment with a combination of fluvastatin and MBV or IL-33, a cytokine contained within MBV. Finally, this therapy can be further combined with AAV-based gene therapy blocking anti-regenerative pathways in RGCs to extend regenerated axons. These data highlight novel molecular insights into the development of immunomodulatory regenerative therapy.

Abstract Over the past five decades, a large number of wild animals have been individually identified by various observation systems and/or temporary tracking methods, providing unparalleled insights into their lives over both time and space. However, so far there is no comprehensive record of uniquely individually identified animals nor where their data and metadata are stored, for example photos, physiological and genetic samples, disease screens, information on social relationships. Databases currently do not offer unique identifiers for living, individual wild animals, similar to the permanent ID labelling for deceased museum specimens. To address this problem, we introduce two new concepts: (1) a globally unique animal ID (UAID) available to define uniquely and individually identified animals archived in any database, including metadata archived at the time of publication; and (2) the digital ‘home’ for UAIDs, the Movebank Life History Museum (MoMu), storing and linking metadata, media, communications and other files associated with animals individually identified in the wild. MoMu will ensure that metadata are available for future generations, allowing permanent linkages to information in other databases. MoMu allows researchers to collect and store photos, behavioural records, genome data and/or resightings of UAIDed animals, encompassing information not easily included in structured datasets supported by existing databases. Metadata is uploaded through the Animal Tracker app, the MoMu website, by email from registered users or through an Application Programming Interface (API) from any database. Initially, records can be stored in a temporary folder similar to a field drawer, as naturalists routinely do. Later, researchers and specialists can curate these materials for individual animals, manage the secure sharing of sensitive information and, where appropriate, publish individual life histories with DOIs. The storage of such synthesized lifetime stories of wild animals under a UAID (unique identifier or ‘animal passport’) will support basic science, conservation efforts and public participation.

Abstract The signature feature of the ‘strange metal’ state of high-T c cuprates—its linear-in-temperature resistivity—has a coefficient α 1 that correlates with T c , as expected were α 1 derived from scattering off the same bosonic fluctuations that mediate pairing. Recently, an anomalous linear-in-field magnetoresistance (=γ 1 H) has also been observed, but only over a narrow doping range, leaving its relation to the strange metal state and to the superconductivity unclear. Here, we report in-plane magnetoresistance measurements on three hole-doped cuprate families spanning a wide range of temperatures, magnetic field strengths and doping. In contrast to expectations from Boltzmann transport theory, γ 1 is found to correlate universally with α 1. A phenomenological model incorporating real-space inhomogeneity is proposed to explain this correlation. Within this picture, superconductivity in hole-doped cuprates is governed not by the strength of quasiparticle interactions with a bosonic bath, but by the concentration of strange metallic carriers.

The performance of electrochemical energy devices, such as fuel cells and batteries, is dictated by intricate physiochemical processes within. To better understand and rationally engineer these processes, we need robust operando characterization tools that detect and distinguish multiple interacting components/interfaces in high contrast. Here, we uniquely combine dual-modality tomography (simultaneous neutron and x-ray tomography) and advanced image processing (iterative reconstruction and metal artifact reduction) for high-contrast multimaterial imaging, with signal and contrast enhancements of up to 10 and 48 times, respectively, compared to conventional single-modality imaging. Targeted development and application of these methods to electrochemical devices allow us to resolve operando distributions of six interacting fuel cell components (including void space) with the highest reported pairwise contrast for simultaneous yet decoupled spatiotemporal characterization of component morphology and hydration. Such high-contrast tomography ushers in key gold standards for operando electrochemical characterization, with broader applicability to numerous multimaterial systems.

INTRODUCTION: A periodical self-monitoring of spherical refraction using smartphones may potentially allow a quicker intervention by eye care professionals to reduce myopia progression. Unfortunately, at low levels of myopia, the far point (FP) can be located far away from the eye which can make interactions with the device difficult. To partially remedy this issue, a novel method is proposed and tested wherein the longitudinal chromatic aberration (LCA) of blue light is leveraged to optically bring the FP closer to the eye. METHODS: Firstly, LCA was obtained by measuring spherical refraction subjectively using blue pixels in stimuli shown on organic light-emitting diode (OLED) screens and also grey stimuli with matching luminance. Secondly, the visual acuity (VA) measured with a smartphone located at 1.0 m and 1.5 m and displaying blue optotypes was compared with that obtained clinically standard measurements. Finally, the spherical over refraction obtained in blue light with a smartphone was compared with clinical over-refraction with black and white (B&W) optotypes placed at 6 m. RESULTS: Mean LCA of blue OLED smartphone screens was -0.67 ± 0.11 D. No significant differences (p > 0.05) were found between the VA measured with blue optotypes on a smartphone screen and an eye chart. Mean difference between spherical over-refraction measured subjectively by experienced subjects with smartphones and the one obtained clinically was 0.08 ± 0.34 D. CONCLUSIONS: Smartphones using blue light can be used as a tool to detect changes in visual acuity and spherical refraction and facilitate monitoring of myopia progression.

Abstract Quantum materials are often characterized by a marked sensitivity to minute changes in their physical environment, a property that can lead to new functionalities and thereby, to novel applications. One such key property is the magneto-elastoresistance (MER), the change in magnetoresistance (MR) of a metal induced by uniaxial strain. Understanding and modeling this response can prove challenging, particularly in systems with complex Fermi surfaces. Here, we present a thorough analysis of the MER in the nearly compensated Dirac nodal-line semi-metal ZrSiSe. Small amounts of strain (0.27%) lead to large changes (7%) in the MR. Subsequent analysis reveals that the MER response is driven primarily by a change in transport mobility that varies linearly with the applied strain. This study showcases how the effect of strain tuning on the electrical properties can be both qualitatively and quantitatively understood. A complementary Shubnikov-de Haas oscillation study sheds light on the root of this change in quantum mobility. Moreover, we unambiguously show that the Fermi surface consists of distinct electron and hole pockets revealed in quantum oscillation measurements originating from magnetic breakdown.

Background: The management of heart failure (HF) is challenging because of the complexities in recommended therapies. Integrated disease management (IDM) is an effective model, promoting guideline-directed care, but the impact of IDM in the community setting requires further evaluation. Methods: A retrospective evaluation of community-based IDM. Patient characteristics were described, and outcomes using a pre- and post-intervention design were HF-related health-service use, quality of life, and concordance with guideline-directed medical therapy (GDMT). Results: 715 patients were treated in the program (2016 to 2023), 219 in a community specialist–care clinic, and 496 in 25 primary-care clinics. The overall cohort was predominantly male (60%), with a mean age of 73.5 years (± 10.7), and 60% with HF with reduced ejection fraction. In patients with ≥ 6 months of follow-up (n = 267), pre vs post annualized rates of HF-related acute health-service use decreased from 36.3 to 8.5 hospitalizations per 100 patients per year, P < 0.0001, from 31.8 to 13.1 emergency department visits per 100 patients per year, P < 0.0001, and from 152.8 to 110.0 urgent physician visits per 100 patients per year, P = 0.0001. The level of concordance with GDMT improved; the number of patients receiving triple therapy and quadruple therapy increased by 10.1% (95% confidence interval [CI], 2.4%,17.8%) and 19.6% (95% CI, 12.0%, 27.3%), respectively. Within these groups, optimal dosing was achieved in 42.5% (95% CI, 32.0%, 53.6%) and 35.0% (95% CI, 23.1%, 48.4%), respectively. In patients with at least one follow-up visit (n = 286), > 50% experienced a clinically relevant improvement in their quality of life. Conclusions: A community-based IDM program for HF, may reduce HF-related acute health-service use, improve quality of life and level of concordance with GDMT. These encouraging preliminary outcomes from a real-world program evaluation require confirmation in a randomized controlled trial. Résumé: Contexte: La prise en charge de l’insuffisance cardiaque (IC) représente un défi en raison de la complexité des traitements recommandés. La prise en charge intégrée des maladies est un modèle efficace qui favorise les soins reposant sur les lignes directrices, mais la portée de ce modèle en milieu extra-hospitalier mérite une évaluation plus approfondie. Méthodologie: Évaluation rétrospective de la prise en charge intégrée des maladies à l’échelle communautaire. Les caractéristiques des patients ont été établies. Les résultats mesurés avant et après l’intervention ont été l’utilisation des services de santé liés à l’IC, la qualité de vie et le degré de concordance avec le traitement médical recommandé par les lignes directrices. Résultats: Au total, 715 patients ont été traités dans le cadre du programme (de 2016 à 2023) : 219 dans une clinique communautaire de soins spécialisés et 496 dans 25 cliniques de soins primaires. Dans l’ensemble, la majorité des patients étaient de sexe masculin (60 %). L’âge moyen était de 73,5 ans (± 10,7 ans). Soixante pour cent des patients présentaient une IC avec fraction d’éjection réduite. Chez les patients ayant fait l’objet d’un suivi pendant ≥ 6 mois (n = 267), les taux annualisés d’utilisation des services de santé aigus liés à l’IC avant et après l’intervention sont passés de 36,3 à 8,5 hospitalisations pour 100 patients par année (p < 0,0001), de 31,8 à 13,1 visites aux urgences pour 100 patients par année (p < 0,0001) et de 152,8 à 110,0 consultations avec un urgentologue pour 100 patients par année (p = 0,0001). On a observé une augmentation du degré de concordance avec le traitement médical recommandé par les lignes directrices. Le nombre de patients recevant une trithérapie et une quadrithérapie a également augmenté de 10,1 % (intervalle de confiance [IC] à 95 % : 2,4 % à 17,8 %) et de 19,6 % (IC à 95 % : 12,0 % à 27,3 %), respectivement. Dans ces groupes, la dose optimale a été atteinte chez 42,5 % (IC à 95 % : 32,0 % à 53,6 %) et 35,0 % (IC à 95 % : 23,1 % à 48,4 %) des patients, respectivement. Plus de 50 % des patients ayant effectué au moins une visite de suivi (n = 286) ont obtenu une amélioration cliniquement pertinente de leur qualité de vie. Conclusions: Un programme communautaire de prise en charge intégrée de l’IC peut réduire l’utilisation des services de santé liés à l’IC, améliorer la qualité de vie et augmenter le degré de concordance avec le traitement médical recommandé par les lignes directrices. Bien qu’ils soient encourageants, ces résultats préliminaires issus de l’évaluation d’un programme en contexte réel doivent être confirmés par la réalisation d’une étude à répartition aléatoire et contrôlée.

Background: Menopause is a significant period in the life of a female; many hormonal and lifestyle changes occur, which can have a catastrophic effect on their health and well-being. Amongst these changes is the loss of muscle mass and strength. Resistance training is recommended for post-menopausal women; however, the role of protein in muscle mass and strength in this population is unclear. Methods: This narrative review discusses the research evidence regarding daily protein needs, dose and timings of intake, and protein quality. Results: Observational and interventional studies suggest post-menopausal females should ingest at least the RDA 0.8 g·kg−1·d−1 of protein, the dosing at each meal maybe important. Both whey and soy protein may provide some benefit to muscle strength. Conclusions: Overall, there is limited evidence and not of high quality, making it difficult to make inferences about the protein needs of post-menopausal females.

PurposePersonal mobile devices such as smartphones are proving their usefulness in ever more applications in tele-eyecare. An inconvenience and potential source of error in these past approaches stemmed from the requirement for the subjects to situate their devices at a distance. The present study aims to clinically validate best corrected visual acuity (BCVA) measures carried out by a novel smartphone application "vision.app" (VisionApp Solutions S.L.) using comparative statistics against clinical measurements.Materials and methodsBCVA was measured in both eyes of 40 subjects using vision.app which displayed a black Landolt-C optotype with crowding on a white background, and utilized a 4 forced-choice procedure for the subjects to find (by means of swiping in either of four directions) the smallest optotype size they could resolve. Results were compared to BCVA measurements taken using a standard Snellen chart placed at 20 feet (6 m).ResultsThe t-test revealed no significant differences between the app- and clinically-measured VA (p = 0.478 (OD) and 0.608 (OS)), with a mean difference between clinical and app measurements of less than one line of the eye chart (-0.009 logMAR (OD) and -0.005 logMAR (OS)). A limit of agreement for a 95% confidence interval of ± 0.08 logMAR for OD and OS was found.ConclusionsThe results show the potential use of a smartphone to measure BCVA at a handheld distance. The newly validated study results can hold major future advancements in tele-eyecare and provide eye care professionals with a reliable and accessible method to measure BCVA.